BUSINESS: Roche acquires Genentech for $46.8B


Leading biotech company Roche, parent company of Roche Molecular Diagnostics in Pleasanton, annouced yesterday that it has reached an agreement to purchase San Francisco-based Genentech for $46.8 billion.

The merger means Swiss drugmaker Roche will acquire Genentech for $95 per share.

In a statement released by Roche, the company says the merger will make Roche the seventh largest U.S. pharmaceuticals company in terms of market share. The combined company's U.S. commercial operations in pharmaceuticals will operate under the Genentech name.

Roche is a world leader in in-vitro diagnostics and drugs for cancer and transplantation.

--Janet Pelletier


Sorry, but further commenting on this topic has been closed.

Couples: Wanting, Yet Missing One Another
By Chandrama Anderson | 0 comments | 929 views

Superintendent's new contract may portend difficult employee negotiations
By Tim Hunt | 8 comments | 687 views

Scott Raty bows out as CEO of Pleasanton Chamber
By Jeb Bing | 0 comments | 399 views

Trends for the Class of 2019 to Consider
By Elizabeth LaScala | 0 comments | 110 views


Nominations due by Sept. 17

Pleasanton Weekly and are once again putting out a call for nominations and sponsorships for the annual Tri-Valley Heroes awards - our salute to the community members dedicated to bettering the Tri-Valley and the lives of its residents.

Nomination form